Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: A clinical report

Marie Marchand; C. J.A. Punt; S. Aamdal; B. Escudier; W. H.J. Kruit; U. Keilholz; L. Håkansson; N. Van Baren; Y. Humblet; P. Mulders; M. F. Avril; A. M.M. Eggermont; C. Scheibenbogen; J. Uiters; J. Wanders; M. Delire; T. Boon; G. Stoter

doi:10.1016/S0959-8049(02)00479-3

Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: A clinical report

Marie Marchand, C. J.A. Punt, S. Aamdal, B. Escudier, W. H.J. Kruit, U. Keilholz, L. Håkansson, N. Van Baren, Y. Humblet, P. Mulders, M. F. Avril, A. M.M. Eggermont, C. Scheibenbogen, J. Uiters, J. Wanders, M. Delire, T. Boon, G. Stoter

Research output: Contribution to journal › Article › peer-review

162 Citations (Scopus)

Abstract

Fifty-seven patients with MAGE-3-positive measurable metastatic cancer, most of them with melanoma, were vaccinated with escalating doses of a recombinant MAGE-3 protein combined with a fixed dose of the immunological adjuvant SBAS-2, which contained MPL and QS21. The immunisation schedule included 4 intramuscular (i.m.) injections at 3-week intervals. Patients whose tumour stabilised or regressed after 4 vaccinations received 2 additional vaccinations at 6-week intervals. The vaccine was generally well tolerated. Among the 33 melanoma patients who were evaluable for tumour response, we observed 2 partial responses, 2 mixed responses and 1 stabilisation. Time to progression in these 5 patients varied from 4 to 29 months. In addition, a partial response lasting 10 months was observed in 1 of the 3 metastatic bladder cancer patients included. None of the tumour responses described above involved visceral metastases. Immunological responses to the vaccine will be reported separately.

Original language	English
Pages (from-to)	70-77
Number of pages	8
Journal	European Journal of Cancer
Volume	39
Issue number	1
DOIs	https://doi.org/10.1016/S0959-8049(02)00479-3
Publication status	Published - Jan 2003
Externally published	Yes

Keywords

Antibodies
Cancer
Immunological adjuvant SBAS-2
Immunotherapy
MAGE-3 protein
Melanoma
T lymphocyte

Access to Document

10.1016/S0959-8049(02)00479-3

Cite this

Marchand, M., Punt, C. J. A., Aamdal, S., Escudier, B., Kruit, W. H. J., Keilholz, U., Håkansson, L., Van Baren, N., Humblet, Y., Mulders, P., Avril, M. F., Eggermont, A. M. M., Scheibenbogen, C., Uiters, J., Wanders, J., Delire, M., Boon, T., & Stoter, G. (2003). Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: A clinical report. European Journal of Cancer, 39(1), 70-77. https://doi.org/10.1016/S0959-8049(02)00479-3

@article{8dad2c3298e945ccacee9bfbf598933f,

title = "Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: A clinical report",

abstract = "Fifty-seven patients with MAGE-3-positive measurable metastatic cancer, most of them with melanoma, were vaccinated with escalating doses of a recombinant MAGE-3 protein combined with a fixed dose of the immunological adjuvant SBAS-2, which contained MPL and QS21. The immunisation schedule included 4 intramuscular (i.m.) injections at 3-week intervals. Patients whose tumour stabilised or regressed after 4 vaccinations received 2 additional vaccinations at 6-week intervals. The vaccine was generally well tolerated. Among the 33 melanoma patients who were evaluable for tumour response, we observed 2 partial responses, 2 mixed responses and 1 stabilisation. Time to progression in these 5 patients varied from 4 to 29 months. In addition, a partial response lasting 10 months was observed in 1 of the 3 metastatic bladder cancer patients included. None of the tumour responses described above involved visceral metastases. Immunological responses to the vaccine will be reported separately.",

keywords = "Antibodies, Cancer, Immunological adjuvant SBAS-2, Immunotherapy, MAGE-3 protein, Melanoma, T lymphocyte",

author = "Marie Marchand and Punt, {C. J.A.} and S. Aamdal and B. Escudier and Kruit, {W. H.J.} and U. Keilholz and L. H{\aa}kansson and {Van Baren}, N. and Y. Humblet and P. Mulders and Avril, {M. F.} and Eggermont, {A. M.M.} and C. Scheibenbogen and J. Uiters and J. Wanders and M. Delire and T. Boon and G. Stoter",

note = "Funding Information: We gratefully acknowledge the following Institutions and clinical investigators for their participation in this study: Amsterdam Cancer Institute (G.C. de Gast); Amsterdam Free University (W. Gerritsen); Institut Jules Bordet, Brussels (F. Lehmann); Centre pluridisciplinaire d'Oncologie and Ludwig Institute for Cancer Research, Lausanne Branch, Lausanne (D. Li{\'e}nard); and Cliniques Universitaires de Mont Godinne, University of Louvain, Yvoir (J. Kerger). This work was supported by the Fortis Bank-Assurances and VIVA (Belgium).",

year = "2003",

month = jan,

doi = "10.1016/S0959-8049(02)00479-3",

language = "English",

volume = "39",

pages = "70--77",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "Elsevier Ltd.",

number = "1",

}

Marchand, M, Punt, CJA, Aamdal, S, Escudier, B, Kruit, WHJ, Keilholz, U, Håkansson, L, Van Baren, N, Humblet, Y, Mulders, P, Avril, MF, Eggermont, AMM, Scheibenbogen, C, Uiters, J, Wanders, J, Delire, M, Boon, T & Stoter, G 2003, 'Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: A clinical report', European Journal of Cancer, vol. 39, no. 1, pp. 70-77. https://doi.org/10.1016/S0959-8049(02)00479-3

TY - JOUR

T1 - Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2

T2 - A clinical report

AU - Marchand, Marie

AU - Punt, C. J.A.

AU - Aamdal, S.

AU - Escudier, B.

AU - Kruit, W. H.J.

AU - Keilholz, U.

AU - Håkansson, L.

AU - Van Baren, N.

AU - Humblet, Y.

AU - Mulders, P.

AU - Avril, M. F.

AU - Eggermont, A. M.M.

AU - Scheibenbogen, C.

AU - Uiters, J.

AU - Wanders, J.

AU - Delire, M.

AU - Boon, T.

AU - Stoter, G.

N1 - Funding Information: We gratefully acknowledge the following Institutions and clinical investigators for their participation in this study: Amsterdam Cancer Institute (G.C. de Gast); Amsterdam Free University (W. Gerritsen); Institut Jules Bordet, Brussels (F. Lehmann); Centre pluridisciplinaire d'Oncologie and Ludwig Institute for Cancer Research, Lausanne Branch, Lausanne (D. Liénard); and Cliniques Universitaires de Mont Godinne, University of Louvain, Yvoir (J. Kerger). This work was supported by the Fortis Bank-Assurances and VIVA (Belgium).

PY - 2003/1

Y1 - 2003/1

N2 - Fifty-seven patients with MAGE-3-positive measurable metastatic cancer, most of them with melanoma, were vaccinated with escalating doses of a recombinant MAGE-3 protein combined with a fixed dose of the immunological adjuvant SBAS-2, which contained MPL and QS21. The immunisation schedule included 4 intramuscular (i.m.) injections at 3-week intervals. Patients whose tumour stabilised or regressed after 4 vaccinations received 2 additional vaccinations at 6-week intervals. The vaccine was generally well tolerated. Among the 33 melanoma patients who were evaluable for tumour response, we observed 2 partial responses, 2 mixed responses and 1 stabilisation. Time to progression in these 5 patients varied from 4 to 29 months. In addition, a partial response lasting 10 months was observed in 1 of the 3 metastatic bladder cancer patients included. None of the tumour responses described above involved visceral metastases. Immunological responses to the vaccine will be reported separately.

AB - Fifty-seven patients with MAGE-3-positive measurable metastatic cancer, most of them with melanoma, were vaccinated with escalating doses of a recombinant MAGE-3 protein combined with a fixed dose of the immunological adjuvant SBAS-2, which contained MPL and QS21. The immunisation schedule included 4 intramuscular (i.m.) injections at 3-week intervals. Patients whose tumour stabilised or regressed after 4 vaccinations received 2 additional vaccinations at 6-week intervals. The vaccine was generally well tolerated. Among the 33 melanoma patients who were evaluable for tumour response, we observed 2 partial responses, 2 mixed responses and 1 stabilisation. Time to progression in these 5 patients varied from 4 to 29 months. In addition, a partial response lasting 10 months was observed in 1 of the 3 metastatic bladder cancer patients included. None of the tumour responses described above involved visceral metastases. Immunological responses to the vaccine will be reported separately.

KW - Antibodies

KW - Cancer

KW - Immunological adjuvant SBAS-2

KW - Immunotherapy

KW - MAGE-3 protein

KW - Melanoma

KW - T lymphocyte

UR - http://www.scopus.com/inward/record.url?scp=0037215111&partnerID=8YFLogxK

U2 - 10.1016/S0959-8049(02)00479-3

DO - 10.1016/S0959-8049(02)00479-3

M3 - Article

C2 - 12504661

AN - SCOPUS:0037215111

SN - 0959-8049

VL - 39

SP - 70

EP - 77

JO - European Journal of Cancer

JF - European Journal of Cancer

IS - 1

ER -

Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: A clinical report

Abstract

Keywords

Access to Document

Fingerprint

Cite this